Clinical value of plasma exosome circLPAR1 in the diagnosis and prognostic evaluation of gastric cancer

doi:10.3877/cma.j.issn.2095-2015.2025.04.003

Abstract

Abstract:

Objective

To measure the expression level of plasma exosome circLPAR1 in the serum of gastric cancer patients, and to analyze the clinical value of circLPAR1 in the diagnosis and prognosis assessment of gastric cancer.

Methods

A retrospective cohort study design was adopted. A total of 98 gastric cancer patients newly diagnosed at the Dongcheng Campus of the First Affiliated Hospital of Anhui Medical University from March 2018 to March 2019 were selected as the research subjects. At the same time, 60 patients with chronic gastritis and 60 healthy examinees were selected. The expression level of plasma exosomal circLPAR1 in each group was detected by real-time quantitative polymerase chain reaction (RT-qPCR). The diagnostic values of plasma exosomal circLPAR1, serum carcinoembryonic antigen (CEA), and serum carbohydrate antigen 19-9 (CA19-9) in gastric cancer were analyzed. The relationship between plasma exosomal circLPAR1 and the clinicopathological characteristics of gastric cancer patients was analyzed, and the survival curve was drawn by the Kaplan-Meier method.

Results

The expression level of plasma exosomal circLPAR1 in gastric cancer patients was lower than that in patients with chronic gastritis and healthy examinees, with statistically significant differences (P<0.05). The level of plasma exosomal circLPAR1 was correlated with tissue differentiation, tumor diameter, vascular invasion, lymph node metastasis, and TNM stage (P<0.05). The average survival time of gastric cancer patients with high expression of serum exosomal circLPAR1 was longer than that of the low expression group. Receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve (AUC) of plasma exosomal circLPAR1 was 0.960 (95% CI: 0.916-0.984), which was significantly higher than the AUC value of single serum CEA detection (0.708, 95% CI: 0.630-0.777) and single serum CA19-9 detection (0.724, 95% CI: 0.647-0.792).

Conclusion

The expression level of plasma exosomal circLPAR is increased in gastric cancer patients. The level of plasma exosomal circLPAR is related to the clinicopathological characteristics and prognosis of gastric cancer patients. The detection of plasma exosomal circLPAR has high sensitivity and specificity in the diagnosis of gastric cancer, and has certain clinical application value.

Key words: Gastric cancer, Exosome, Diagnosis, Prognosis

Jun Wang, Juan Chen, Qianhong Liu. Clinical value of plasma exosome circLPAR1 in the diagnosis and prognostic evaluation of gastric cancer[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(04): 300-304.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.04.003

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I04/300

Figures/Tables 5

References 20

[1]	左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58.
[2]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[3]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4]	Arnold M, Abnet CC, Neale RE, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer[J]. Gastroenterology, 2020, 159(1): 335-349. e15.
[5]	范清泉. 外泌体在胃癌中的研究展望[J]. 外科理论与实践, 2023, 28(2): 177-180.
[6]	蒋进勋, 张世杰, 王震. 外泌体在胃癌诊疗中的研究进展[J]. 中国肿瘤临床, 2023, 50(4): 201-205.
[7]	Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer[J]. Mol Cancer, 2017, 23; 16(1): 94.
[8]	郑留昌, 李俊蒙, 郑培明. 血清外泌体circRPS6在结直肠癌患者诊断及预后评估中的临床价值[J]. 中华检验医学杂志, 2024, 47(3): 272-277.
[9]	Zheng R, Zhang K, Tan S, et al. Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3-eIF3h interaction[J]. Mol Cancer, 2022, 21(1): 49.
[10]	Yang X, Xia J, Peng C, et al. Expression of plasma exosomal circLPAR1 in patients with gastric cancer and its clinical application value[J]. Am J Cancer Res, 2023, 13(9): 4269-4276.
[11]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2022, 102(16): 1169-1189.
[12]	Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project[J]. Gastric Cancer, 2017, 20(2): 217-225.
[13]	Lin G, Sheng H, Xie H, et al. circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762[J]. Oncol Lett, 2019, 17(3): 3537-3547.
[14]	Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer[J]. Mol Ther Nucleic Acids, 2019, 16: 118-129.
[15]	Shao Y, Li J, Lu R, et al. Global circular RNA expression profile of human gastric cancer and its clinical significance[J]. Cancer Med, 2017, 6(6): 1173-1180.
[16]	Chen Y, Yao L, Tang Y, et al. CircNet 2.0: an updated database for exploring circular RNA regulatory networks in cancers[J]. Nucleic Acids Res, 2022, 50(D1): D93-D101.
[17]	Ghosal S, Das S, Sen R, et al. Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits[J]. Front Genet, 2013, 4: 283.
[18]	Wang M, Yu F, Li P, et al. Emerging Function and Clinical Significance of Exosomal circRNAs in Cancer[J]. Mol Ther Nucleic Acids, 2020, 21: 367-383.
[19]	Li M, Jiang M, Meng J, et al. Exosomes: Carriers of Pro-Fibrotic Signals and Therapeutic Targets in Fibrosis[J]. Curr Pharm Des, 2019, 25(42): 4496-4509.
[20]	Yang X, Xia J, Peng C, et al. Expression of plasma exosomal circLPAR1 in patients with gastric cancer and its clinical application value[J]. Am J Cancer Res, 2023, 13(9): 4269-4276.

因素	高表达组(n=49)	低表达组(n=49)	χ²/t	P
性别			0.165	0.685
男	21(42.86)	23(46.94)
女	28(57.14)	26(53.06)
年龄			0.165	0.685
<60岁	21(42.86)	23(46.94)
≥60岁	28(57.14)	26(53.06)
组织分化程度			15.675	0.000
低	9(18.37)	28(57.14)
中-高	40(81.63)	21(42.86)
肿瘤直径			8.030	0.005
<5 cm	16(32.65)	30(61.22)
≥5 cm	33(67.35)	19(38.78)
血管浸润			5.709	0.017
是	21(42.86)	10(20.41)
否	28(57.14)	39(79.59)
淋巴结转移			14.154	0.000
是	23(46.94)	6(12.24)
否	26(53.06)	43(87.76)
TNM分期			9.323	0.002
Ⅰ~Ⅱa期	29(59.18)	14(28.57)
Ⅱb~Ⅲ期	20(40.82)	35(71.43)

因素	高表达组(n=49)	低表达组(n=49)	χ²/t	P
性别			0.165	0.685
男	21(42.86)	23(46.94)
女	28(57.14)	26(53.06)
年龄			0.165	0.685
<60岁	21(42.86)	23(46.94)
≥60岁	28(57.14)	26(53.06)
组织分化程度			15.675	0.000
低	9(18.37)	28(57.14)
中-高	40(81.63)	21(42.86)
肿瘤直径			8.030	0.005
<5 cm	16(32.65)	30(61.22)
≥5 cm	33(67.35)	19(38.78)
血管浸润			5.709	0.017
是	21(42.86)	10(20.41)
否	28(57.14)	39(79.59)
淋巴结转移			14.154	0.000
是	23(46.94)	6(12.24)
否	26(53.06)	43(87.76)
TNM分期			9.323	0.002
Ⅰ~Ⅱa期	29(59.18)	14(28.57)
Ⅱb~Ⅲ期	20(40.82)	35(71.43)

方法	AUC	SE	截断值	95% CI	Youden指数	P	灵敏度(%)	特异性(%)
circLPAR1	0.960	0.021	≤0.69	0.916-0.984	0.873	<0.001	98.98	88.33
CEA	0.708	0.042	≤0.5	0.630-0.777	0.343	<0.001	64.29	70.00
CA19-9	0.724	0.041	≤34.18	0.647-0.792	0.390	<0.001	67.35	71.67

方法	AUC	SE	截断值	95% CI	Youden指数	P	灵敏度(%)	特异性(%)
circLPAR1	0.960	0.021	≤0.69	0.916-0.984	0.873	<0.001	98.98	88.33
CEA	0.708	0.042	≤0.5	0.630-0.777	0.343	<0.001	64.29	70.00
CA19-9	0.724	0.041	≤34.18	0.647-0.792	0.390	<0.001	67.35	71.67

Please choose a citation manager

Content to export